Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

This study tests a combination of two cancer drugs — brentuximab vedotin (a targeted antibody that delivers chemotherapy directly to cancer cells) and bendamustine (a chemotherapy drug) — in people with follicular lymphoma that has come back or stopped responding to prior treatment and has a protein called CD30 on the cancer cells. **You may be eligible if...** - You have been diagnosed with relapsed or refractory follicular lymphoma (grade I, II, or IIIa) that tests CD30-positive - You have measurable disease on CT or PET scan - You have received at least one prior treatment - You are in reasonably good health (ECOG performance status 0–2) - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - Your cancer does not have CD30 expression - You have another active cancer - You are pregnant or breastfeeding - You have active infections (HIV, hepatitis) - You have severe nerve damage (peripheral neuropathy) - Your heart is not able to handle the treatment safely Talk to your doctor to see if this trial is right for you.